Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

Lilly Opens Phase 3 Clinical Trial in RET-Mutant Medullary Thyroid Cancer

americanpharmaceuticalreviewJanuary 02, 2020

Tag: Lilly , thyroid cancer , MTC , selpercatinib

PharmaSources Customer Service